These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24508951)

  • 21. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
    Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
    Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
    Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
    J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.
    Sposato B; Scalese M; Latorre M; Scichilone N; Matucci A; Milanese M; Masieri S; Rolla G; Steinhilber G; Rosati Y; Vultaggio A; Folletti I; Baglioni S; Bargagli E; Di Tomassi M; Pio R; Pio A; Maccari U; Maggiorelli C; Migliorini MG; Vignale L; Pulerà N; Carpagnano GE; Foschino Barbaro MP; Perrella A; Paggiaro PL
    Respir Med; 2016 Oct; 119():141-149. PubMed ID: 27692136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.
    Molimard M; Mala L; Bourdeix I; Le Gros V
    Respir Med; 2014 Apr; 108(4):571-6. PubMed ID: 24565601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe asthma in obese patients: Improvement of lung function after treatment with omalizumab.
    Oliveira MJ; Vieira M; Coutinho D; Ladeira I; Pascoal I; Ferreira J; da Silva JM; Carvalho A; Lima R
    Pulmonology; 2019; 25(1):15-20. PubMed ID: 30827349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eligibility for treatment with omalizumab in Italy and Germany.
    Buhl R; Marco AG; Cohen D; Canonica GW
    Respir Med; 2014 Jan; 108(1):50-6. PubMed ID: 24315468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study.
    Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
    J Asthma; 2023 Oct; 60(10):1862-1868. PubMed ID: 36971065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lung function parameters in omalizumab responder patients: An interesting tool?
    Paganin F; Mangiapan G; Proust A; Prudhomme A; Attia J; Marchand-Adam S; Pellet F; Milhe F; Melloni B; Bernady A; Raspaud C; Nocent C; Berger P; Guilleminault L
    Allergy; 2017 Dec; 72(12):1953-1961. PubMed ID: 28517027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.
    Gibson PG; Reddel H; McDonald VM; Marks G; Jenkins C; Gillman A; Upham J; Sutherland M; Rimmer J; Thien F; Katsoulotos GP; Cook M; Yang I; Katelaris C; Bowler S; Langton D; Robinson P; Wright C; Yozghatlian V; Burgess S; Sivakumaran P; Jaffe A; Bowden J; Wark PA; Yan KY; Kritikos V; Peters M; Hew M; Aminazad A; Bint M; Guo M
    Intern Med J; 2016 Sep; 46(9):1054-62. PubMed ID: 27350385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life long-term omalizumab therapy in children with severe allergic asthma.
    Deschildre A; Marguet C; Langlois C; Pin I; Rittié JL; Derelle J; Abou Taam R; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2015 Sep; 46(3):856-9. PubMed ID: 26022964
    [No Abstract]   [Full Text] [Related]  

  • 32. The relationship between allergen immunotherapy and omalizumab for treating asthma.
    Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
    Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study.
    Tiotiu A; Oster JP; Roux PR; Nguyen Thi PL; Peiffer G; Bonniaud P; Dalphin JC; de Blay F
    J Investig Allergol Clin Immunol; 2020; 30(1):49-57. PubMed ID: 30931917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review.
    Colombo GL; Di Matteo S; Martinotti C; Oselin M; Valentino MC; Bruno GM; Pitotti C; Menzella F
    Ther Adv Respir Dis; 2019; 13():1753466619841350. PubMed ID: 31035904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
    Abraham I; Alhossan A; Lee CS; Kutbi H; MacDonald K
    Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial.
    Yorgancıoğlu A; Öner Erkekol F; Mungan D; Erdinç M; Gemicioğlu B; Özşeker ZF; Bayrak Değirmenci P; Naycı S; Çilli A; Erdenen F; Kırmaz C; Ediger D; Yalçın AD; Büyüköztürk S; Öztürk S; Güleç M; Işık SR; Kalyoncu AF; Göksel Ö; Aydın Ö; Havlucu Y; Baloğlu Ar İ; Erdoğdu A
    Int Arch Allergy Immunol; 2018; 176(3-4):225-233. PubMed ID: 29772578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.